Presenting Author Information	n	
Name (First, Last, Credentials):Elizab	eth Klein, BS	
Institutional Affiliation: Ohio University	sity - Heritage College of Osteopath	ic Medicine
Email Address:lk338118@ohio.edu		
Early Career (Defined as physicians, s	scientists, medical students, and other	er healthcare providers currently in residency
or fellowship programs or within three	e years of training)?	Yes ⊠ No □
Co-author Information		
Name: Amanda Beering, MD Email: Network	amanda.beering@thechristhospital.c	com Affiliation: The Christ Hospital
Name: Robert Dowling, MD Email: 1	obert.dowling@thechristhospital.co	m Affiliation: The Christ Hospital
Network		
Name: Miriam Freundt, MD Email: 1	miriam.freundt@thechristhospital.co	om Affiliation: The Christ Hospital Network
Disclosures: Please list any relevant RD has been reimbursed by Abiomed		
Abstract Topic (must be gende	er- or sex-specific)	
☐ Preventative cardiology	☐ General cardiology	☐ Interventional cardiology
	☐ Cardio-oncology	☐ Cardio-obstetrics
☐ Electrophysiology	☐ Cardiovascular Imaging	☐ Coronary Microvasculature
☐ Social Determinants of Health	☐ Mental Health	☐ Precision Medicine
Title:		
	chanical Circulatory Support in I	Postpartum Cardiomyopathy: A New
Background:		
Postpartum cardiomyopathy can resul		ck with the need for mechanical circulatory and the need for systemic anticoagulation.
	riod, MCS presents a risk for severe	uterine bleeding (SUB). We present a new
vaginal delivery of a healthy daughter	. Due to shock with severe end-orga	ed cardiogenic shock eight weeks after un failure, she was placed on femoral veno- nsitioned to a percutaneous left ventricular

Methods: A 22-year-old female with no past medical history experienced cardiogenic shock eight weeks after vaginal delivery of a healthy daughter. Due to shock with severe end-organ failure, she was placed on femoral veno arterial extracorporeal membrane oxygenation. After stabilization, she transitioned to a percutaneous left ventricular assist device (axillary Impella 5.5) and percutaneous right ventricular assist device (jugular Protek Duo). Her end-organ function normalized but she showed no signs of myocardial recovery and was listed for heart transplantation. On day ten of MCS she had worsening uterine bleeding which was treated with anticoagulation, cessation, administration of hormonal therapy (medroxyprogesterone and misoprostol) and a pro-coagulant (tranexamic acid). Despite these efforts uterine bleeding persisted, resulting in acute blood loss anemia requiring multiple blood transfusions.

Results:

In order to avoid transfusion of blood products which are known to cause allosensitization, and therefore increase the risk of heart transplant rejection, she underwent successful trans-femoral bilateral uterine artery embolization (UAE). This resulted in rapid hemostasis and allowed for continued MCS until a donor heart became available. She underwent successful heart transplantation and is doing fine seven months after with regular uncomplicated menstrual periods.

Conclusions:

Uterine artery embolization is an effective and safe method to rapidly control SUB in female patients on MCS. If utilized early enough, UAE may allow avoidance of blood product transfusion and continuation of anticoagulation to avoid pump thrombosis.

Tables/Figures/Graphics: Include images that are part of your submission here. Images should be high resolution and have a file type of "gif", "jpg", or "jpeg".